Pluviaendo Visuals Pluviaendo Visuals

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viking Therapeutics to Present Data from Phase 2 Study of VK2809 in Non-Alcoholic Fatty Liver Disease Patients with Elevated LDL-Cholesterol","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$350.0 million","upfrontCash":"Undisclosed","newsHeadline":"Viking Therapeutics Announces Proposed Public Offering of Common Stock","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$550.0 million","upfrontCash":"Undisclosed","newsHeadline":"Viking Therapeutics Announces Pricing of $550 Million Public Offering of Common Stock","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$632.5 million","upfrontCash":"Undisclosed","newsHeadline":"Viking Therapeutics Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viking Therapeutics Announces Completion of Enrollment in Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viking Therapeutics Presents New Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) at The Liver Meeting\u00ae 2023","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals for VK2809

    Menu

    VK2809

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Viking Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Viking Therapeutics Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares

              Details:

              The net proceeds from the offering for continued development of its VK2809, a small molecule selective thyroid hormone receptor beta agonist. It is currently being evaluated in a Phase 2b study for for the treatment of non-alcoholic steatohepatitis and fibrosis.

              Lead Product(s): VK2809

              Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: VK2809

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Morgan Stanley

              Deal Size: $632.5 million Upfront Cash: Undisclosed

              Deal Type: Public Offering March 04, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Viking Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Viking Therapeutics Announces Pricing of $550 Million Public Offering of Common Stock

              Details:

              The net proceeds from the offering for continued development of its VK2809, a small molecule selective thyroid hormone receptor beta agonist. It is currently being evaluated in a Phase 2b study for for the treatment of non-alcoholic steatohepatitis and fibrosis.

              Lead Product(s): VK2809

              Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: VK2809

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Morgan Stanley

              Deal Size: $550.0 million Upfront Cash: Undisclosed

              Deal Type: Public Offering February 28, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Viking Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Viking Therapeutics Announces Proposed Public Offering of Common Stock

              Details:

              The net proceeds from the proposed offering for continued development of its VK2809, small molecule selective thyroid hormone receptor beta agonist. It is being evaluated in clinical studies for the treatment of non-alcoholic steatohepatitis and fibrosis.

              Lead Product(s): VK2809

              Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: VK2809

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Morgan Stanley

              Deal Size: $350.0 million Upfront Cash: Undisclosed

              Deal Type: Public Offering February 27, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Viking Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Viking Therapeutics Presents New Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) at The Liver Meeting® 202...

              Details:

              VK2809 novel liver-selective thyroid hormone receptor beta agonist,which is being evaluated for the treatment of patients with biopsy-confirmed non-alcoholic steatohepatitis.

              Lead Product(s): VK2809

              Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: VK2809

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 13, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Viking Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)

              Details:

              VK2809 is an orally available, selective agonist of the thyroid beta receptor, suggesting promising therapeutic potential in a range of lipid disorders. Drug is currently being evaluated for biopsy-confirmed non-alcoholic steatohepatitis.

              Lead Product(s): VK2809

              Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: VK2809

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 16, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Viking Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Viking Therapeutics Announces Completion of Enrollment in Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)

              Details:

              VK2809 is an orally available, selective agonist of the thyroid beta receptor, suggesting promising therapeutic potential in a range of lipid disorders. Drug is currently being evaluated in a Phase 2b clinical trial for biopsy-confirmed non-alcoholic steatohepatitis.

              Lead Product(s): VK2809

              Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: VK2809

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 09, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Viking Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Viking Therapeutics to Present Data from Phase 2 Study of VK2809 in Non-Alcoholic Fatty Liver Disease Patients with Elevated LDL-Cholesterol

              Details:

              Data from the company's 12-week Phase 2 study of VK2809 in patients with non-alcoholic fatty liver disease (NAFLD) and elevated low-density lipoprotein cholesterol (LDL-C) will be presented at the Digital International Liver Congress™ 2020.

              Lead Product(s): VK2809

              Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: VK2089

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 20, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.
              Axplora- The partner of choice for complex APIs.
              Post Enquiry
              POST ENQUIRY